Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease
Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026. The US Food and Drug Administration (FDA) has granted priority review to the new drug...
Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease May 28, 2026 Download PDF Share Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease Paris, May 28, 2026 . The US Food and Drug Administration (FDA) has granted priority review to the new drug application (NDA) for venglustat, a novel, investigational oral glucosylceramide synthase inhibitor (GCSi), for the treatment of type 3 Gaucher disease (GD3)
saved by
related reading
- A new brain‐penetrant glucosylceramide synthase inhibitor as potential Therapeutics for Gaucher diseasepmc.ncbi.nlm.nih.gov
- Eliglustat - Wikipediaen.wikipedia.org
- New Genzyme pill will cost patients $310,250 a year - The Boston Globeweb.archive.org
- GBA Variants and Parkinson Disease: Mechanisms and Treatmentspmc.ncbi.nlm.nih.gov
- Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birthpmc.ncbi.nlm.nih.gov
- [object Object]alliancegenome.org
- UGCG and the glycosphingolipid rheostat: a metabolic checkpoint governing immune activation and tumor immune evasion | Signal Transduction and Targeted Therapynature.com
- Targeting UGCG overcomes resistance to lysosomal autophagy inhibitionpmc.ncbi.nlm.nih.gov
- Medical breakthroughs in 2025 - by Saloni Dattaniscientificdiscovery.dev
- Gaucher disease: Pathogenesis, clinical manifestations, and diagnosisuptodate.com
- The 23andMe Deal - Cremieux Recueilcremieux.xyz
- Nature's drug database - The Works in Progress Newsletterworksinprogress.news